Physician

Mohamad Ahmad Younes, M.D.

According to 2025 Medicare claims, Mohamad Younes, M.D. (NPI: 1366635047) practices hematology/oncology in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is NEW YORK ONCOLOGY HEMATOLOGY, P.C. (NPI: 1609863448; TIN: 141799724) and primary practice location at 12206-5014.

Younes' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 944 traditional Medicare patients, billed 150,048 HCPCS/CPT codes, and received $2,249,761 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,541 prescription claims across 259 beneficiaries totaling $1,677,411 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 16 claims. Open Payments data shows 6 records totaling $12,957. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $946,806 to $2,249,761. Similarly, Part D prescription costs have risen steadily, from $392,688 to $1,677,411. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	510	82,070	$946,806
2016	578	141,982	$1,780,098
2017	723	139,868	$1,615,631
2018	781	95,759	$1,319,036
2019	844	114,377	$1,473,557
2020	820	115,293	$1,678,942
2021	856	143,173	$1,791,546
2022	984	129,223	$1,812,661
2023	860	115,498	$1,723,396
2024	944	150,048	$2,249,761

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	177	1,087	$392,688
2016	187	1,602	$1,400,061
2017	226	1,460	$1,206,725
2018	161	806	$737,623
2019	154	866	$1,131,796
2020	175	1,021	$1,011,504
2021	191	1,094	$1,298,107
2022	226	1,363	$1,964,442
2023	239	1,457	$1,193,565
2024	259	1,541	$1,677,411

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$3,757
2016	N/R	20	$19,626
2017	N/R	33	$10,826
2018	N/R	22	$2,147
2019	N/R	32	$4,236
2020	N/R	27	$2,108
2021	N/R	47	$2,927
2022	N/R	38	$1,492
2023	N/R	N/R	N/R
2024	N/R	16	$301

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	230	291	$62
80053	Blood test, comprehensive group of blood chemicals	530	1,025	$10
36415	Insertion of needle into vein for collection of blood sample	621	1,179	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	623	1,279	$8
83615	Lactate dehydrogenase (enzyme) level	313	436	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	15	450	$206,944
Ibrance	Palbociclib	13	364	$197,592
Eliquis	Apixaban	238	8,627	$165,168
Lenalidomide	Lenalidomide	15	420	$140,166
Procrit	Epoetin Alfa	24	672	$75,729

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$39	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$12,918	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohamad Ahmad Younes, M.D.?

Tedicare shows public-source Medicare data for Mohamad Ahmad Younes, M.D. (NPI 1366635047), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohamad Ahmad Younes, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mohamad Ahmad Younes, M.D.?

Mohamad Ahmad Younes, M.D. is linked to NEW YORK ONCOLOGY HEMATOLOGY, P.C. (billing NPI 1609863448) in the available physician profile data.

Does Mohamad Ahmad Younes, M.D. have Open Payments data?

Mohamad Ahmad Younes, M.D. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.